Sickle Cell Disease Regional Care Excellence (SoRCE) Program

The Sickle Cell Disease Regional Care Excellence (SoRCE) Program is a forecasted funding initiative administered by the Health Resources and Services Administration (HRSA), part of the U.S. Department of Health and Human Services. This program is aligned under the Sickle Cell Treatment Demonstration Program (Assistance Listing 93.365) and aims to significantly improve health outcomes for individuals living with sickle cell disease (SCD) across the United States. HRSA is a federal agency responsible for improving access to healthcare services for people who are uninsured, isolated, or medically vulnerable, and it has a long-standing role in supporting public health programs that enhance the quality and accessibility of care. The purpose of the SoRCE Program is to expand and enhance care quality for the approximately 100,000 individuals in the U.S. who suffer from sickle cell disease. Early and sustained treatment of SCD, beginning in childhood, is known to prevent serious health complications such as painful crises, silent strokes, and premature mortality. Despite universal newborn screening in the U.S., a significant number of children do not receive adequate treatment, and care transitions into adulthood are often marked by inadequate therapeutic interventions and gaps in provider expertise. The SoRCE Program seeks to address these gaps by funding seven regional awardees to serve as Regional Coordinating Hubs (RCHs), each responsible for coordinating efforts across clinical and community-based partners to ensure better access to and quality of care. The program will support these regional hubs in implementing continuous quality improvement (CQI) initiatives. Each RCH is expected to build collaborative networks that include healthcare institutions, clinics, community-based organizations, and other stakeholders that provide or support care for individuals with SCD. The program encourages recipients to not only expand direct service delivery capacity but also to engage in data collection and tracking of quality of life indicators. These indicators will be used to evaluate the impact of services and support future improvements. While the program allows for broad implementation strategies, applicants must be prepared to deliver measurable outcomes across access, treatment, and quality of life domains. There is no cost-sharing or matching requirement for this opportunity, allowing a wider range of applicants to compete equitably. Eligible applicants include public and private institutions of higher education, hospitals, clinics, nonprofits (with or without 501(c)(3) status), and health centers. This inclusive eligibility list ensures that a variety of institutions, including those on the frontlines of care delivery, can apply. Each eligible organization must demonstrate capacity to coordinate regional networks and lead CQI efforts, including the ability to engage community-level partners and integrate care models effectively. The application submission process will be conducted electronically through Grants.gov. Applications are expected to be available starting April 15, 2026, with a due date of June 1, 2026, by 11:59 p.m. Eastern Time. The estimated award date is August 1, 2026, and the performance period is expected to begin on September 1, 2026. No pre-application elements such as letters of intent or concept papers are listed in the forecasted opportunity. As a forecasted opportunity, this information is subject to change upon the release of the full Notice of Funding Opportunity (NOFO). For further information, applicants may contact the Maternal and Child Health Bureau at 240-438-6795 or via email at [email protected]. At this time, no PDF NOFO has been made publicly available, and potential applicants should monitor Grants.gov for updates following the estimated post date. This opportunity does not recur on a rolling basis, nor is there evidence of annual recurrence; therefore, it is expected to be a standalone initiative or one with a longer update interval.